At the last ASCO Annual Meeting Saad et al. presented a report about a Phase II trial of custirsen (OGX-011) + docetaxel + prednisone vs. custirsen + mitoxantrone + prednisone in metastatic hormone-refractory prostate cancer. The subjects in the study had experienced relapses of cancer progression within 6 months of treatment with first-line docetaxel therapy. [...]
The last few days have seen a lot of commotion and celebrating in the prostate cancer world. There have been multiple news stories of an experimental prostate cancer drug, abiraterone, that has been reported to dramatically shrink prostate cancer tumors and extend survival in 70 to 80 percent of men with aggressive prostate cancer. Abiraterone [...]
See the end of this post for information about additional trials that are using Ipilimumab and currently recruiting men with hormone refractory prostate cancer. A multi-site PHASE I study with 33 men has found that a drug called Ipilimumab, also known as MDX-010, has been shown to be able to stimulate the body's own immune [...]
I have been very negligent in not writing about my experience at the American Association of Cancer Researchers (AACR) annual meeting that I attended last month. I found that there was so much information, experiences and emotions that I came away feeling very awed and somewhat over whelmed by the experience. I am still [...]
One of the options for treatment your oncologist may recommend is for you to participate in a clinical trial. Clinical trials are carefully designed research studies that answer specific questions regarding the effectiveness and safety of new drugs, combinations of drugs, treatments, surgical techniques, or medical devices. Human volunteers with specific health conditions are studied [...]